Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cilengitide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 known ✓ | P05106 | 11/20 | 0.59 |
| ▸ | ITGAV known ✓ | P06756 | 11/20 | 0.59 |
| ▸ | ITGB5 known ✓ | P18084 | 6/20 | 0.59 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.59 |
| ▸ | ITGB6 | P18564 | 1/20 | 0.59 |
| ▸ | MC4R | P32245 | 9/20 | 0.52 |
| ▸ | MC5R | P33032 | 9/20 | 0.52 |
| ▸ | MC3R | P41968 | 9/20 | 0.52 |
| ▸ | MC1R | Q01726 | 9/20 | 0.52 |
| ▸ | ITGA5 | P08648 | 3/20 | 0.51 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cilengitide SCHEMBL16920496 | 1.00 | ITGB3 (0.59) | ITGB3ITGAVITGB5ITGA2BITGB6 | |
| Cilengitide SCHEMBL22594705 | 1.00 | ITGB3 (0.59) | ITGB3ITGAVITGB5ITGA2BITGB6 | |
| SCHEMBL16923811 | 0.94 | ITGB3 (0.52) | ITGB3ITGAVITGB5ITGA2BITGB6 | |
| SCHEMBL19595173 | 0.93 | ITGB3 (0.49) | ITGB3ITGAVITGB5ITGA2BITGB6 | |
| SCHEMBL12467279 | 0.93 | ITGB3 (0.49) | ITGB3ITGAVITGB5ITGA2BITGB6 | |
| SCHEMBL27360546 | 0.90 | ITGB3 (0.49) | ITGB3ITGAVITGB5ITGA2BITGB6 | |
| SCHEMBL12468724 | 0.90 | ITGB3 (0.47) | ITGB3ITGAVITGB5ITGA2BITGB6 | |
| SCHEMBL24202406 | 0.89 | ITGB3 (0.48) | ITGB3ITGAVITGB5ITGA2BITGB6 | |
| SCHEMBL22807659 | 0.89 | ITGB3 (0.48) | ITGB3ITGAVITGB5ITGA2BITGB6 | |
| SCHEMBL16920494 | 0.89 | ITGB3 (0.51) | ITGB3ITGAVITGB5ITGA2BITGB6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1296 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577255-B2 | MDM2-based modulators of proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-03-17 | — | — | US | claimed |
| EP-4704832-A2 | BIFUNCTIONAL SMALL MOLECULES TO TARGET THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS | Biohaven Therapeutics Ltd. (VG) | 2026-03-11 | — | — | EP | claimed |
| US-12564728-B2 | Treatment of central nervous system disorders | KNOW BIO, LLC (US) | 2026-03-03 | — | — | US | claimed |
| US-20260022117-A1 | COMPOUNDS AND METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS | ARVINAS OPERATIONS INC (US) | 2026-01-22 | — | — | US | claimed |
| US-12485178-B2 | Bifunctional small molecules to target the selective degradation of circulating proteins | YALE UNIVERSITY (US) | 2025-12-02 | — | — | US | claimed |
| US-20250332274-A1 | BIFUNCTIONAL SMALL MOLECULES TO TARGET THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS | UNIV YALE (US) | 2025-10-30 | — | — | US | claimed |
| US-12364766-B2 | Bifunctional small molecules to target the selective degradation of circulating proteins | YALE UNIVERSITY (US) | 2025-07-22 | — | — | US | claimed |
| CN-119591582-A | Imide-based proteolytic modulators and related methods of use | 阿尔维纳斯运营股份有限公司 | 2025-03-11 | — | — | CN | claimed |
| CN-119591543-A | Bis-aminoquinolines and nano-formulations for cancer treatment | 加利福尼亚大学董事会 | 2025-03-11 | — | — | CN | claimed |
| EP-4493222-A2 | BIFUNCTIONAL SMALL MOLECULES TO TARGET THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS | Yale University (US) | 2025-01-22 | — | — | EP | claimed |
| US-20220280807-A1 | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | KNOW BIO, LLC | 2022-09-08 | — | — | US | claimed |
| CN-115023418-A | Bis-aminoquinoline and nanoformulation for cancer treatment | 加利福尼亚大学董事会 | 2022-09-06 | — | — | CN | claimed |
| US-20220267329-A1 | Dihydro-Spiro[Indoline-3:1'-Isoquinolin]-2-Ones and Their Analogues and Derivatives and Methods of Treating Cancer and Other Diseases | THE UNIV OF BUEA (CM) | 2022-08-25 | — | — | US | claimed |
| WO-2022169634-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | UNM RAINFOREST INNOVATIONS (US) | 2022-08-11 | — | — | WO | claimed |
| EP-4031543-A1 | BIAMINOQUINOLINES AND NANOFORMULATIONS FOR CANCER TREATMENT | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-07-27 | — | — | EP | claimed |
| US-20220202950-A1 | COMPOSITIONS COMPRISING BACTERIALLY DERIVED INTACT MINICELLS FOR THERANOSTIC APPLICATIONS | ENGENEIC MOLECULAR DELIVERY PTY LTD (AU) | 2022-06-30 | — | — | US | claimed |
| EP-4010072-A2 | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | KNOW Bio, LLC (US) | 2022-06-15 | — | — | EP | claimed |
| US-20220088029-A1 | COMBINATION THERAPY OF TETRACYCLIC QUINOLONE ANALOGS FOR TREATING CANCER | SENHWA BIOSCIENCES INC (TW) | 2022-03-24 | — | — | US | claimed |
| US-20220089570-A1 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | Arvinas, Inc. | 2022-03-24 | — | — | US | claimed |
| CN-114206435-A | Treatment of central nervous system disorders | 诺欧生物有限责任公司 | 2022-03-18 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260022117-A1 | COMPOUNDS AND METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS | VHL, ADRM1, MDM2 | ITGB3 3255/4885ITGAV 3329/4885ITGB5 3408/4885 |
| US-12485178-B2 | Bifunctional small molecules to target the selective degradation of circulating proteins | ASGR1, LDLR, FCGR2A | ITGB3 224/4885ITGAV 267/4885ITGB5 229/4885 |
| US-12577255-B2 | MDM2-based modulators of proteolysis and associated methods of use | MDM2, UBR4, UBE3A | ITGB3 4006/4885ITGAV 3939/4885ITGB5 4202/4885 |
| US-20250332274-A1 | BIFUNCTIONAL SMALL MOLECULES TO TARGET THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS | ASGR1, LDLR, FCGR3B | ITGB3 167/4885ITGAV 293/4885ITGB5 137/4885 |
| US-20220088029-A1 | COMBINATION THERAPY OF TETRACYCLIC QUINOLONE ANALOGS FOR TREATING CANCER | CXCR4, CXCR6, TLR7 | ITGB3 4108/4885ITGAV 3021/4885ITGB5 2581/4885 |
| US-20220089570-A1 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | CRBN, MDM2, UBE2N | ITGB3 4646/4885ITGAV 4698/4885ITGB5 4285/4885 |
| US-12564728-B2 | Treatment of central nervous system disorders | BDNF, NTRK2, CNTN1 | ITGB3 597/4885ITGAV 1231/4885ITGB5 998/4885 |
| US-20220267329-A1 | Dihydro-Spiro[Indoline-3:1'-Isoquinolin]-2-Ones and Their Analogues and Derivatives and Methods of Treating Cancer and Other Diseases | S1PR3, S1PR1, S1PR2 | ITGB3 2425/4885ITGAV 3438/4885ITGB5 1985/4885 |
| US-12364766-B2 | Bifunctional small molecules to target the selective degradation of circulating proteins | ASGR1, LDLR, FCGR3B | ITGB3 167/4885ITGAV 293/4885ITGB5 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.